6YC Stock Chart & Stats
€0.47
€0.01(2.11%)
At close: 4:00 PM EST
€0.47
€0.01(2.11%)
Day’s Range― - ―
52-Week Range€0.32 - €0.75
Previous CloseN/A
Volume0.00
Average Volume (3M)660.00
Market Cap
€54.39M
Enterprise Value€665.00
Total Cash (Recent Filing)€37.11M
Total Debt (Recent Filing)€21.37M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding157,215,040
10 Day Avg. Volume480
30 Day Avg. Volume660
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€13.84M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthSenzime’s very low debt-to-equity (~0.08) reduces solvency and interest-rate risk, giving the company financial flexibility to support commercialization and absorb near-term losses. That balance-sheet strength lengthens runway and limits immediate refinancing pressure while execution on cash flow continues.
Installed Base & Recurring ConsumablesAn installed base exceeding 5,500 monitors and >1,000,000 monitored patients creates durable recurring revenues from consumable sensors. High sensor growth (rolling 12M +27%, sensors driving majority of revenue) supports predictable aftermarket demand and margin leverage over time.
Margin Improvement & New Service ModelMaterial gross margin improvement (underlying ~69.2%) plus early traction with TetraGraph-as-a-Service (faster closes, 120 units deployed) indicate sustainable product economics. Higher ASPs, pricing actions, and a service model increase lifetime value and improve the path to structural profitability.
Bears Say
High Cash Burn / Negative Cash FlowSustained, large negative operating and free cash flow (TTM roughly -88M and -97M) creates persistent funding needs. Even with available credit and some cash on hand, continued burn raises dilution or refinancing risk if revenue and margin gains slip, pressuring long‑term financial sustainability.
Deeply Negative Profitability And Declining MomentumDespite scale-up of revenues historically, net margins remain deeply negative (~-121%) and recent TTM revenue growth has reversed, indicating the company still runs an operating cost base that outpaces sales. Converting to sustainable profits requires sustained execution and volume leverage.
Execution Risks From Sales Cycles & Regulatory TimingRevenue realization depends on slow hospital/IDN procurement and regional regulatory approvals; recent delayed U.S. deals and Asian timing issues show this risk. Such structural sales-cycle and approval delays can defer consumable adoption and compress near-term cash flow despite strong pipeline.
Senzime AB News
6YC FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was €0.32 and its highest was €0.75 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is €54.39M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Oct 29, 2026 which is in 101 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Jul 16, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.14%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in DE:6YC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―







